CHICAGO, IL—Two new drugs targeting lipoprotein(a)—one a small interfering RNA (siRNA), the other an oral agent that prevents its formation—both showed positive results in early phase II studies, with ...
The Eli Lilly drug caused a major drop in the blood levels of Lp(a), but further research is needed to show that it will prevent heart attacks and strokes. By Gina Kolata As many as one in five people ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback